Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aim: to communicate home parenteral nutrition (HPN) data obtained from the HPN registry of the NADYA-SENPE group (www.nadya-senpe.com) for the year 2018 Material and methods: descriptive analysis of the data collected from adult and pediatric patients with HPN in the NADYA-SENPE group registry from January 1st, 2018 to December 31st, 2018. Results: there were 278 patients from 45 Spanish hospitals (54.7% women), 23 children and 255 adults, which represent a prevalence rate of 5.95 patients/million inhabitants/year 2018. The most frequent diagnosis in adults was "palliative cancer" (22.0%), followed by "others". In children it was Hirschsprung's disease together with necrotizing enterocolitis, with four cases (17.4%). The first indication was short bowel syndrome in both children (60.9%) and adults (35.7%). The most frequently used type of catheter was tunneled in both children (81.0%) and adults (41.1%). Ending 75 episodes, the most frequent cause was death (52.0%) and change to oral feeding (33.3%). Conclusions: the number of centers and collaborating professionals in the registry of patients receiving HPN remains stable, as well as the main indications and reasons for termination of HPN.

Download full-text PDF

Source
http://dx.doi.org/10.20960/nh.02976DOI Listing

Publication Analysis

Top Keywords

parenteral nutrition
8
nadya-senpe group
8
hpn
5
[home ambulatory
4
ambulatory artificial
4
artificial nutrition
4
nutrition nadya
4
nadya group
4
group report
4
report parenteral
4

Similar Publications

Home parenteral nutrition (HPN) is a life-sustaining therapy traditionally used as a bridge to enteral autonomy or intestinal transplantation. Increasingly, it is used for intractable feeding intolerance (IFI), which can occur near the end of life (EOL) in children with severe neurological impairment (SNI). In these cases, HPN use differs from its historical role and requires tailored outpatient planning.

View Article and Find Full Text PDF

Background: Intravenous lipid emulsions are a key component of parenteral nutrition, and their fatty acid compositions may influence immune responses and clinical outcomes.

Methods: This retrospective cohort study conducted from January 2020 to December 2022 compared clinical outcomes of hospitalized non-critical care patients receiving parenteral nutrition with either mixed oil or soybean oil lipid emulsions for at least 48 h. The primary outcome was a composite of the presence of pneumonia, urinary tract infection, or an intra-abdominal collection diagnosed within 14 days of initiating parenteral nutrition.

View Article and Find Full Text PDF

Background: The association between Teicoplanin (TEIC) total trough concentration (C) and adverse effects (hepatotoxicity, nephrotoxicity, and thrombocytopenia) in patients with hypoalbuminemia remains poorly understood. We examined this association for patients with hypoalbuminemia from a safety perspective.

Methods: This retrospective study included adult patients (≥18 years) who received TEIC at Kyushu Medical Center between April 2013 and March 2024, underwent therapeutic drug monitoring, and had persistent serum albumin < 2.

View Article and Find Full Text PDF

The Home Artificial Nutrition Unit (HANU) deals with both dysphagic patients receiving enteral and parenteral nutrition and patients who can eat orally with restrictions. In the Lazio Region, the HANU prescribes water gels and thickeners, supplied by the National Health Service (NHS), for safe hydration. Before the employment of a Speech and Language Pathologist (SLP) in the HANU (January 2023), prescriptions were standardized, regardless of the swallowing impairment severity: four jars of thickeners per patient/month and six water gels daily.

View Article and Find Full Text PDF

Introduction: Efficacy and safety of a novel total parenteral nutrition formula for chronic kidney disease patients, OPF-109, containing multivitamins based on the FDA2000 recommendation were investigated.

Methods: We conducted a phase III clinical trial administering OPF-109 (n=63) or the control solutions (combination of marketed products including multivitamin based on American Medical Association 1975 guidelines) (n=61) to the chronic kidney disease patients for 8 days. Blood concentrations of proteins and vitamins and safety were evaluated.

View Article and Find Full Text PDF